The latest edition of the Provider's Digest, HCPLive's monthly newsletter spotlighting regulatory decisions and pipeline news, is now live! In our July 2024 recap, we spotlight 9 FDA decisions, 6 submissions or new designations, and 5 topline data announcements. Be sure to subscribe for a recap of the therapies, companies, and individuals moving the needle in healthcare during the past month, delivered on the first Saturday of each new month! #FDANews #Healthcare #Medicine
HCPLive
Media Production
Cranbury, NJ 3,295 followers
Comprehensive clinical news that provide clinicians with up-to-date specialty and disease-specific information.
About us
HCPLive provides health care professionals with up-to-date specialty and disease-specific news, clinical information, and other resources to help provide better care to patients. On HCPLive.com, you will find in-depth conference coverage and information about upcoming meetings, perspective on regulatory news, and multimedia content featuring key opinion leaders. Get all the latest news on individual medical conditions in our "condition centers": • Cardiology • Endocrinology • Gastroenterology • Ophthalmology • Neurology • Pain Management • Pediatrics • Primary Care • Psychiatry • Rheumatology • Urology
- Website
-
http://www.HCPLive.com
External link for HCPLive
- Industry
- Media Production
- Company size
- 2-10 employees
- Headquarters
- Cranbury, NJ
- Type
- Privately Held
- Founded
- 1957
- Specialties
- Managed Care, primary care, family medicine, Healthcare news, Internal Medicine, Medicine, Medical News, FDA News, and Cardiology
Locations
-
Primary
2 Clarke Drive
Suite 100
Cranbury, NJ 08512, US
Employees at HCPLive
Updates
-
A new study in JAMA reported a notable increase in heat-related mortality rates in the US between 1999 and 2023, particularly during the last 7 years. The investigative team, led by Jeffrey Howard, PhD at The University of Texas at San Antonio, examined the Centers for Disease Control and Prevention WONDER Platform for relevant ICD codes over more than 20 years. Find out more: https://lnkd.in/eBiXy6Yq #PublicHealth #ClimateChange
-
-
The Dexcom Stelo, the first FDA-cleared OTC glucose sensor, became available yesterday. This morning, we published a special edition #DiabetesDialogue with Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES and Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCES bringing you their first-hand perspective after a day using the device. Learn about their initial impressions of the device and where it might find a role in health management: https://lnkd.in/e7DKjs8B #Diabetes #Healthcare
-
Check out the latest edition of Qazi Corner, our quarterly newsletter from Taha Qazi, MD, and members of the Cleveland Clinic! In this installment, we showcase perspectives from Chiara M., MD, Rajat Garg, MD, and David Long, DO, on seronegative villous atrophy, safety of early vs late ERCP, and considerations around GLP-1 RA use in preprocedure planning for endoscopy, respectively. Learn more: https://lnkd.in/em8Gm8xr #Gastroenterology #QaziCorner
-
-
August 26, 2024 marks the beginning of a new age in glucose monitoring as Dexcom has announced the availability of the Stelo—the first FDA-cleared OTC glucose sensor. According to Dexcom, each Stelo sensor offers 15-day wear, is HSA/FSA eligible, and can be purchased for as low as $89.99 per 2-pack with a monthly subscription. https://lnkd.in/e8jTnETi #Diabetes #Healthcare Jake Leach
-
-
In a recent interview, Jocelyn Y. Cheng, MD, of the American Academy of Sleep Medicine offered advice on how healthcare providers can create an environment in which patients feel more comfortable talking about their physical and mental symptom burden of dialysis. For more perspective, check out our latest feature on the importance of addressing sleep health during dialysis: https://lnkd.in/e_wVYX7a #Sleep #Nephrology
-
ICYMI: A prespecified analysis of the SELECT trial, led by John Deanfield CBE, A. Michael Lincoff, Ildiko Lingvay, and others, details the effects of semaglutide 2.4 mg (Wegovy; Novo Nordisk) among patients with heart failure within the landmark trial. Learn more: https://lnkd.in/eWUAUjC2 #Cardiology #HeartFailure
-
-
Sunday Spotlight 🌟: This year, #ESCCongress will continue its legacy of showcasing groundbreaking research in cardiovascular medicine, with the meeting boasting 12 Hot Line sessions and dozens of late-breaking trials. In a recent interview, Deepak L. Bhatt, MD, MPH, MBA, of Icahn School of Medicine at Mount Sinai, shared his insights with HCPLive Cardiology on the trials he’s most excited about. https://lnkd.in/eAJdAg3q Here’s a quick look at some of the key trials to watch: FINEARTS-HF: Hot Line 7, Sunday, September 1, 11:00 AM BST EMPACT-MI KIDNEY: Late-Breaking Science, Sunday, September 1, 09:00 AM BST ABYSS trial: Hot Line 1, Friday, August 30, 11:00 AM BST STOP-OR-NOT: Hot Line 1, Friday, August 30, 11:00 AM BST RESHAPE-HF2: Hot Line 3, Saturday, August 31, 11:00 AM BST NOTION-3: Hot Line 5, Saturday, August 31, 5:35 PM BST SHAM-PVI: Hot Line 1, Monday, September 2, 11:00 AM BST Stay tuned for in-depth coverage of these and other key findings from ESC Congress 2024! #ESC2024 #Cardiology #ClinicalTrials #HeartHealth
-
New testing study for health care professionals. Participate today! Click the link to see if you qualify: https://bit.ly/4d74wpi
-
-
ICYMI: In a recent #DiabetesDialogue, Muthu Vaduganathan, MD, MPH of Brigham and Women's Hospital, discusses what we know so far about the FINEARTS-HF trial and what he is looking forward to from #ESCCongress with Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, of Cleveland Clinic, and Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCES, of University Hospitals. Learn more: https://lnkd.in/eJc88mMs #HeartFailure